Mesa Laboratories MLAB Clinical Genomics — Cost Of Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's clinical genomics — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's clinical genomics — cost of revenue?
- Mesa Laboratories (MLAB) reported clinical genomics — cost of revenue of $4.79M in Q1 2026.
- How has Mesa Laboratories's clinical genomics — cost of revenue changed year-over-year?
- Mesa Laboratories's clinical genomics — cost of revenue decreased by 7.6% year-over-year, from $5.19M to $4.79M.
- What is the long-term trend for Mesa Laboratories's clinical genomics — cost of revenue?
- Over 2 years (2024 to 2026), Mesa Laboratories's clinical genomics — cost of revenue has grown at a -12.9% compound annual growth rate (CAGR), from $25.51M to $19.36M.
- What does clinical genomics — cost of revenue mean?
- This represents the total direct costs incurred to produce and deliver the products and services sold by the Clinical Genomics segment. It is a primary measure of the segment's direct operational efficiency and production cost structure.